Hidradenitis suppurativa is a chronic inflammatory dermatosis characterized by painful, recurrent nodules, abscesses, and draining tunnels, known as sinus tracts, most commonly in the axillae, groin, and perineal regions. It arises from inflammation centered on the hair follicles in areas rich in apocrine glands, and it follows a relapsing-remitting course that can span decades. The disease is far from rare, affecting an estimated one percent or more of the population, yet it remains underdiagnosed and frequently mistaken for simple boils or infections. Beyond its physical toll, the condition is notorious for its impact on quality of life: lesions in sensitive body regions, malodorous drainage, scarring, and unpredictable flares contribute to social isolation, sexual dysfunction, and profound psychological distress. For years, clinicians have observed that patients with hidradenitis suppurativa suffer from depression, anxiety, and suicidality at rates that dwarf those seen in the general population and in many other chronic dermatologic diseases.

What distinguishes the new research letter by Rehman Basharat of the Renaissance School of Medicine at Stony Brook University and Javed Iqbal of Stony Brook’s Department of Neurobiology and Behavior is its deliberate reversal of the conventional causal arrow. Most prior investigations, including a widely cited 2020 systematic review and meta-analysis published in the Journal of the American Academy of Dermatology, examined depression, anxiety, and suicidality as outcomes of living with hidradenitis suppurativa. That meta-analysis confirmed strikingly elevated odds of psychiatric comorbidity among patients, cementing the skin-to-mind pathway in the literature. The Stony Brook team instead asked whether depression might come first—whether a diagnosis of depression increases the subsequent likelihood of developing hidradenitis suppurativa. By structuring the analysis as a retrospective cohort using real-world data, the investigators could track individuals over time and examine the temporal sequence between the psychiatric and dermatologic conditions, an approach that cross-sectional surveys simply cannot support.

The biologic plausibility of such a reverse pathway rests on a rapidly growing understanding of the immunology of depression itself. Far from being a purely neurochemical disorder, major depression is increasingly recognized to carry a systemic inflammatory signature. Landmark work, including the influential 2016 review by Andrew Miller and Charles Raison in Nature Reviews Immunology, has documented elevated circulating pro-inflammatory cytokines, increased acute-phase reactants, and altered immune cell activity in subsets of depressed patients. Cytokines such as interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha can cross into or signal within the central nervous system, but their effects are by no means confined to the brain. These same molecular messengers are central drivers of cutaneous inflammation. In hidradenitis suppurativa specifically, the pathophysiology is understood to involve follicular occlusion followed by an intense, dysregulated immune response dominated by innate inflammatory pathways and a characteristic overexpression of tumor necrosis factor alpha, interleukin-17, and interleukin-23 in lesional skin. A 2024 narrative review in Skin Appendage Disorders meticulously mapped this cytokine-mediated molecular architecture of the disease, highlighting how TNF-alpha in particular orchestrates the chronic inflammatory cascade that destroys follicular structures and produces the fistulating lesions that define advanced disease.

The convergence of these two inflammatory profiles is what gives the new hypothesis its scientific traction. Depression is associated with elevated TNF-alpha and other cytokines; hidradenitis suppurativa is driven by the same mediators. If a state of chronic, low-grade systemic inflammation induced or maintained by depression were to lower the threshold for follicular inflammation, impair wound healing, or dysregulate the innate immune responses of the skin, then depressed individuals could plausibly face a heightened risk of developing manifest hidradenitis suppurativa. Behavioral and physiological factors common to depression may compound this immunologic pathway: sleep disruption, physical inactivity, smoking, obesity, poor diet, and altered hypothalamic-pituitary-adrenal axis activity are all more prevalent in depression and all have documented links to inflammatory skin disease severity. Cortisol dysregulation, in particular, is known to impair epidermal barrier function and dermal immune surveillance, mechanisms that have been studied extensively in the psychodermatology literature.

The Stony Brook authors are explicit that their work builds on earlier speculation in the field. A 2024 commentary in the journal Cutis raised exactly this possibility, arguing that depression could function as a potential contributing factor in hidradenitis suppurativa and highlighting racial gaps in how the association manifests, given the disease’s disproportionate burden on Black patients and the documented disparities in diagnosis and treatment access. A 2023 literature review in the journal Life catalogued the range of psychiatric disorders associated with hidradenitis suppurativa and explored their potential pathogenesis, concluding that the relationship is almost certainly bidirectional and biologically embedded rather than a simple byproduct of living with visible, painful lesions. By bringing retrospective cohort methodology and real-world data to bear, the new research letter provides an empirical test of what had been largely a hypothesis grounded in mechanistic plausibility and clinical observation.

The real-world data approach deserves particular emphasis, because it addresses a persistent weakness of the hidradenitis suppurativa literature. Randomized trials in the field, including those that established biologics such as TNF-alpha and IL-17 inhibitors as mainstay therapies, enroll selected patients under controlled conditions, and their findings do not always translate cleanly to the heterogeneous populations seen in routine practice. Recent real-world studies, such as 2025 evaluations of biologic therapy effectiveness published in the Australasian Journal of Dermatology, have demonstrated both the value and the limitations of translating trial results into everyday clinical care, including nuances in lipid profiles and treatment safety captured only in broader cohorts. A retrospective cohort built on real-world data captures patients of all disease severities, comorbidity profiles, and demographic backgrounds, offering a view of the depression-hidradenitis axis that reflects the population as it actually presents to clinicians rather than as it appears in protocol-driven trials.

For clinicians, the implications of a depression-to-hidradenitis risk pathway would be considerable. Dermatologists managing patients with early or suspected hidradenitis suppurativa routinely screen for psychiatric comorbidity, and European S1 guidelines for the disease’s treatment explicitly recommend attention to quality of life and psychological burden as part of comprehensive care. But if depression is also a risk factor, the screening logic inverts: psychiatrists and primary care physicians treating depressed patients, particularly those with inflammatory comorbidities, obesity, or smoking, might reasonably maintain a heightened index of suspicion for early follicular inflammation in intertriginous areas, enabling diagnosis before the disease progresses to painful scarring and sinus tract formation. Early intervention matters enormously in this disease, since treatments ranging from wound care and antibiotics to biologics and surgery are far more effective before irreversible structural damage occurs. The findings also raise provocative questions about whether effective depression treatment could modify hidradenitis risk, an intervention trial that no one has yet conducted but that the current study’s results would seem to justify.

The authors are careful to frame their work within the constraints of the retrospective design. Observational cohort data can establish temporal sequence and statistical association, but cannot by itself prove causation; unmeasured confounders, including shared genetic susceptibilities, medication effects, and healthcare utilization patterns, may partly explain the observed relationship. The research letter format likewise signals a concise, focused analysis intended to stimulate further work rather than to settle the question definitively. Both authors contributed to writing the manuscript, with Basharat preparing the figure and table, and both reviewed and approved the final text. The authors declare no competing interests, and the data supporting the findings are provided within the manuscript itself. Correspondence for the study is directed to Javed Iqbal in Stony Brook’s Department of Neurobiology and Behavior.

Nevertheless, the study lands at a moment when the broader concept of the mind-skin axis is gaining scientific respectability. Psychodermatology, once a niche corner of both dermatology and psychiatry, now commands growing attention as immunologic research reveals the molecular common ground between mental states and skin inflammation. The inflammatory hypothesis of depression has prompted trials of anti-inflammatory agents as antidepressant adjuncts; conversely, dermatologists increasingly recognize that calming systemic inflammation can lift mood. Hidradenitis suppurativa, with its uniquely severe psychiatric comorbidity burden and its cytokine biology so clearly intertwined with the inflammatory signature of depression, may prove to be one of the clearest natural laboratories for studying this bidirectional relationship. If future prospective studies confirm that depression accelerates or precipitates the disease, the Standard of care could expand to include collaborative, multidisciplinary management in which mental health treatment is viewed not only as supportive care but as a genuine component of dermatologic prevention. For the millions of patients who endure this condition in silence, often for years before diagnosis, the recognition that their psychological suffering and their skin disease are two faces of a single inflammatory biology represents both scientific progress and long-overdue clinical empathy.

Depression, notoriously recognized for its multifaceted nature, arises from an intertwining of biological, psychological, and social factors. While previous studies have elucidated individual components, the mechanisms detailing how these diverse influences converge within the brain and body have remained elusive. The current study uncovers epigenetic modifications—specifically DNA methylation patterns—as a key mediator that not only influences gene expression but also dynamically shapes one’s vulnerability to depressive symptoms in response to external biopsychosocial stressors.

IL6R is integral to immune system signaling, especially in inflammatory responses. Given the well-documented links between inflammation and depression, the methylation status of the IL6R gene emerges as a compelling candidate for understanding the biological underpinnings of mood disorders. The researchers show that variations in DNA methylation at specific promoter regions of IL6R can alter receptor expression levels, thereby modulating how the body and brain respond to environmental and psychological stressors. This fine-scale epigenetic tuning offers a plausible molecular mechanism linking psychosocial risk factors to neuroimmune pathways implicated in depression.

The study utilized a robust cohort subjected to comprehensive biopsychosocial assessments, including evaluations of stress exposure, social support, and psychological resilience. These data were then meticulously analyzed alongside DNA methylation profiles extracted from peripheral blood samples. Employing state-of-the-art epigenome-wide association methodologies, the team discerned specific CpG sites within the IL6R gene whose methylation levels significantly moderated the strength and directionality of the association between biopsychosocial risks and depressive symptom severity.

Notably, participants displaying higher methylation levels at these CpG loci exhibited a dampened inflammatory response and, correspondingly, a reduced severity of depressive symptoms despite high psychosocial adversity. Conversely, lower methylation correlated with heightened depressive symptomatology, underscoring the functional relevance of these epigenetic marks. These findings introduce the exciting prospect that targeted epigenetic modifications might someday serve as biomarkers for predicting depression risk or as potential therapeutic targets to modulate immune responses in vulnerable individuals.

Crucially, this research advances the growing recognition that depression is not simply a “chemical imbalance” but a dynamic system shaped by genetic predispositions intricately orchestrated by epigenetic processes responsive to life experiences. By situating IL6R methylation at the crossroads of psychosocial stress and biological responses, this study provides a critical piece in the puzzle linking mind and body. It also reconciles prior conflicting reports regarding inflammation’s role in depression by illuminating how epigenetic regulation fine-tunes these responses.

The implications of this work are vast, particularly in the realm of personalized medicine. Epigenetic markers like IL6R methylation could enable clinicians to stratify patients based on molecular profiles, facilitating precision-targeted therapies that go beyond one-size-fits-all antidepressants. Furthermore, these biomarkers could inform interventions integrating psychological and social support tailored to individual biological susceptibilities, fostering holistic treatment paradigms.

This study also offers compelling evidence supporting lifestyle interventions aiming to modify epigenetic landscapes. Emerging research suggests that factors such as diet, exercise, and mindfulness can influence DNA methylation patterns, potentially modulating disease risk. By delineating a concrete epigenetic target linked to depression vulnerability, the IL6R gene methylation findings might galvanize efforts toward integrative approaches combining molecular insights with practical therapeutics.

The technological rigor of the research is equally remarkable. The authors employed advanced methylome sequencing techniques coupled with sophisticated bioinformatics pipelines to capture methylation signatures with high resolution and accuracy. Statistical models accounted for potential confounders including age, gender, and cell type heterogeneity, ensuring robustness and reproducibility of the associations. This methodological precision strengthens the credibility of the proposed epigenetic moderation hypothesis.

Importantly, this investigation sets the stage for future longitudinal studies to unravel the temporal dynamics of IL6R methylation changes in relation to psychosocial stress exposure and depressive episodes. Understanding whether methylation patterns precede symptom onset or result from depression itself remains a critical question. Moreover, expanding research across diverse populations will be vital to confirm the universality or specificity of these epigenetic modulations, ensuring broad applicability.

In the rapidly evolving domain of neuropsychiatric epigenetics, these results represent a significant milestone, highlighting how molecular signatures can bridge the divide between environment and genome function. The ability to map how social experiences get embedded at the molecular level to influence mental health signals a new frontier in psychiatric research, promising novel biomarkers and intervention targets that transcend traditional categorical diagnoses.

Ultimately, by illuminating the epigenetic regulatory landscape of IL6R in the context of biopsychosocial influences, this study reframes depression through a lens of molecular plasticity and integrative biology. It exemplifies the power of interdisciplinary research combining psychiatry, immunology, genetics, and epigenomics to unravel the complex etiologies of mental illness. As scientific understanding deepens, such insights propel us closer to developing truly transformative treatments addressing depression at its molecular roots.

The discovery also prompts a broader contemplation of how epigenetic mechanisms might regulate other neuroimmune genes, potentially orchestrating a systemic biological response to environmental pressures beyond IL6R alone. Future research may identify additional epigenetic modulators acting in concert, weaving an intricate regulatory network underscoring psychiatric disorders’ complexity and heterogeneity.

In conclusion, Kusuma and colleagues’ elucidation of IL6R DNA methylation as a molecular moderator linking biopsychosocial stressors to depression severity opens transformative horizons for research and clinical practice. By integrating epigenetic data with psychosocial factors, this pioneering study strengthens the conceptual foundation for personalized, biologically informed mental health care, promising significant advancements in preventing, diagnosing, and treating depression worldwide.

Subject of Research:
The role of DNA methylation in the IL6R gene in moderating the relationship between biopsychosocial factors and depression.

Article Title:
DNA methylation of the IL6R gene moderates the association between biopsychosocial factors and depression.

Article References:
Kusuma, R.M., Lesmana, M.H.S., Amelia, V.L. et al. DNA methylation of the IL6R gene moderates the association between biopsychosocial factors and depression. Transl Psychiatry (2025). https://doi.org/10.1038/s41398-025-03596-w

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41398-025-03596-w